Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
167 hedge funds and large institutions have $826M invested in Taro Pharmaceutical Industries Ltd. in 2016 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 17 closing their positions.
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
43% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 47
9% more funds holding
Funds holding: 153 → 167 (+14)
9% less capital invested
Capital invested by funds: $910M → $826M (-$84M)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
23% less call options, than puts
Call options by funds: $830K | Put options by funds: $1.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$42M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21.4M |
| 3 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
+$14.3M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$13.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$90M |
| 2 |
TI
Think Investments
San Francisco,
California
|
-$28.8M |
| 3 |
AIM
Assured Investment Management
New York
|
-$18.7M |
| 4 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$7.72M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$7.19M |
TARO Hedge Fund Activity: Q1 2016 in Review
167 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2016, worth a combined $826M — down 9.2% from $910M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TARO positions and 17 closed out — a net gain of 17 holders — while 67 added to existing stakes and 47 trimmed.
The largest buyer was Schroder Investment Management Group, adding an estimated $42M. The largest seller was ISZO Capital Management, exiting entirely with an estimated $90M sold.
- 167 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2016, up from 153 in Q4 2015.
- Funds reported $826M of Taro Pharmaceutical Industries Ltd. stock for Q1 2016, down 9.2% quarter-over-quarter.
- 34 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2016 and 17 closed out, a net change of +17 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2016 was Schroder Investment Management Group, an estimated $42M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2016 was ISZO Capital Management, an estimated $90M sold.
Based on aggregated 13F filings for Q1 2016.